No Data
No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Yunnan Baiyao GroupLtd (SZSE:000538) Shareholders Have Earned a 20% Return Over the Last Year
Yunnan Baiyao Group (000538.SZ) largest Shareholder, the state-owned equity management company, has increased its Shareholding by 17.8075 million shares.
Yunnan Baiyao Group (000538.SZ) announced that from August 6, 2024, to February 5, 2025, the company...
Yunnan Baiyao GroupLtd (SZSE:000538) Has A Pretty Healthy Balance Sheet
The Chief Innovation Officer of Yunnan Baiyao Group, Qin Wanmin, has retired and resigned.
Yunnan Baiyao Group (000538.SZ) announced that the company's Board of Directors recently received reports from the company's Chief Innovation Officer, Senior Vice President...
Yunnan Baiyao Group (000538.SZ): In terms of advantageous OTC channels, a nationwide service has targeted 5,000 leading chains, covering over 0.4 million stores.
On January 10, Gelonghui reported that Yunnan Baiyao Group (000538.SZ) stated during an investor research meeting that, in terms of Pharmaceuticals, the company's marketing network covers Medical Institutions and retail pharmacies across all provinces, regions, counties, and towns in the country. In the advantageous OTC channel, the company has identified services for 5,000 leading chains nationwide, covering over 400,000 stores, particularly achieving high coverage, penetration rates, and strong market control capabilities in well-developed areas such as East China, Hunan, Hubei, and Yunnan, implementing special marketing cooperation with "one province, one policy" and even "one chain, one policy". The company has also partnered with major platforms such as Alibaba, JD.com, and Douyin.